New Hope for Smokers: Cytisinicline Succeeds Where Others Have Failed

BALTIMORE, MD – March 04, 2026 – For the millions of smokers who have tried and failed to quit, often multiple times, a sense of discouragement can be a powerful barrier to trying again. New data presented this week, however, offers a significant ray of hope, suggesting a plant-based drug could succeed where other treatments have fallen short.

At the Society for Research on Nicotine & Tobacco (SRNT) 2026 Annual Meeting, Achieve Life Sciences (Nasdaq: ACHV) unveiled a compelling analysis of its investigational drug, cytisinicline. A pooled analysis of two large-scale Phase 3 trials involving over 1,600 participants demonstrated that the treatment delivered high quit rates, regardless of a person’s history with other smoking cessation medications or the sheer number of their previous quit attempts. The findings arrive at a pivotal moment for the company, which awaits a final decision from the U.S. Food and Drug Administration (FDA) on the drug's approval, expected by this summer.

A Second Chance for Treatment-Resistant Smokers

The most significant takeaway from the new data is cytisinicline's effectiveness in a notoriously difficult-to-treat population. The oral presentation at SRNT combined results from the ORCA-2 and ORCA-3 trials, examining outcomes for smokers who had previously used FDA-approved medications like varenicline (Chantix), bupropion (Zyban), and various nicotine replacement therapies (NRTs) without success. The analysis also stratified participants by whether they had made four or fewer quit attempts versus more than four.

The results were consistent and striking: cytisinicline provided a meaningful benefit across all groups. This suggests the drug could offer a vital new option for individuals who have cycled through existing therapies and may have lost hope in their ability to quit.

“In this analysis, cytisinicline helped people to quit smoking, even those individuals who had failed previous quit attempts or had used FDA-approved smoking cessation medications without success,” said Dr. Nancy Rigotti, a Professor of Medicine at Harvard Medical School and an investigator for the ORCA program. “Many people have to try to quit several times before they become smoke-free. This finding should offer hope to patients whose prior setbacks might have discouraged them from trying to quit smoking again.”

This is more than just a clinical victory; it’s a potential paradigm shift for the 29 million American adults who still smoke. Tobacco use remains the leading cause of preventable death in the United States, responsible for nearly half a million deaths annually. By proving effective in a treatment-resistant population, cytisinicline could help a large, underserved segment of smokers finally break the cycle of addiction.

Poised to Disrupt the Cessation Market

With a Prescription Drug User Fee Act (PDUFA) date set for June 20, 2026, Achieve Life Sciences is on the cusp of potentially entering a multi-billion dollar market. Cytisinicline’s mechanism is similar to that of varenicline, the active ingredient in Chantix, which has long been considered a highly effective prescription option. Both drugs are partial agonists that target nicotinic receptors in the brain, reducing cravings and the rewarding sensation of smoking.

However, cytisinicline may possess a key competitive advantage: a more favorable side-effect profile. In a February 2026 report, the independent Institute for Clinical and Economic Review (ICER) noted that cytisinicline appears to have similar efficacy to varenicline but with potentially less nausea, a common side effect that leads some patients to discontinue treatment. A unanimous ICER panel voted that there is high certainty cytisinicline provides substantial net health benefits compared to behavioral therapy alone, a strong endorsement that could pave the way for favorable insurance coverage.

If approved, cytisinicline would enter a market with established players but also significant unmet needs. Its unique profile as a plant-based alkaloid with a strong efficacy and safety record, particularly in tough-to-treat cases, could allow it to capture a significant market share. For investors, the upcoming PDUFA date is a critical binary event that could transform the late-stage specialty pharmaceutical company into a commercial-stage contender.

Beyond the Cigarette: A Broader War on Nicotine

Achieve’s ambitions for cytisinicline extend beyond traditional cigarettes. The company also presented late-breaking survey data from its ORCA-OL study, an open-label trial where participants used the drug for up to a year. The results highlighted positive patient experiences with extended use, suggesting benefits in maintaining abstinence and improving physical health over the long term. This data contributes to a more complete picture of the drug’s real-world impact as a tool for managing a chronic condition.

More importantly, the company is positioning cytisinicline as a weapon in the fight against the modern nicotine epidemic: vaping. With approximately 17 million adults and 1.6 million middle and high school students in the U.S. using e-cigarettes, there is a pressing need for approved cessation treatments. Currently, no FDA-approved medications are specifically indicated for quitting vaping.

Recognizing this critical gap, the FDA has already granted cytisinicline a Breakthrough Therapy designation for vaping cessation. Achieve has successfully completed a Phase 2 trial for this indication, signaling a clear path forward. This dual-front strategy—addressing both smoking and vaping—could make cytisinicline a uniquely versatile and valuable asset in the public health arsenal against nicotine dependence.

As the health consequences of long-term vaping remain a subject of intense study, having a proven pharmacological tool to help users quit could be transformative, especially for younger generations who are often the primary users of e-cigarettes. With its impending FDA decision for smoking cessation and a clear regulatory pathway for a vaping indication, Achieve Life Sciences is not just launching a new drug; it is aiming to redefine the treatment landscape for nicotine addiction in the 21st century.